<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733145</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00054661</org_study_id>
    <nct_id>NCT03733145</nct_id>
  </id_info>
  <brief_title>Angiotensin II in General Anesthesia</brief_title>
  <official_title>A Dose Finding Trial for Angiotensin II in Hypertensive Adults on Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Anesthesia-Mediated Hypotension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypotension in adult patients undergoing general anesthesia is common. This can lead to
      hypoperfusion of vital organs, organ damage, and states of increased metabolic duress. This
      may be worse in patients with underlying essential hypertension and worse in patients taking
      Angiotensin Converting Enzyme Inhibitors (ACE) and Angiotensin Receptor Blockers (ARBs).
      Intravenous (IV) administration of Ang II may be an effective treatment of hypotension in
      this patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypotension in adult patients undergoing general anesthesia is common. Many of the body's
      normal mechanisms to maintain adequate blood pressure in the non-anesthetized state are
      significantly altered by anesthetic agents, which may lead to hypotension. This can lead to
      hypoperfusion of vital organs, organ damage, and states of increased metabolic duress. In
      response to this it has become standard of care to attempt to maintain blood pressure levels
      within 20% of baseline in most patients under anesthesia. Maintaining the baseline blood
      pressure is important as patients may have pathology such as coronary artery disease, carotid
      stenosis, and renal artery stenosis, and hypotension may compromise the perfusion of these
      organs. Vasodilation also plays a key role in hypotension due to general anesthesia.
      Therefore, the intravenous (IV) administration of Ang II may be an effective treatment of
      hypotension in this patient population.The objective of this study is to determine the
      infusion rate of Ang II that is necessary to return systolic blood pressure (SBP) to within
      5% of baseline or greater in patients with essential hypertension taking ACE inhibitors,
      ARBs, or different classes of antihypertensive agents and further to determine the plasma
      levels of different RAAS components
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 3, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean dose required to increase the SBP</measure>
    <time_frame>up to 1 hour</time_frame>
    <description>The mean dose required to increase the SBP in these 3 cohorts with essential hypertension (ACE inhibitor, ARB, or those on another class of hypertensive agents) to within 5% of baseline or higher will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean value of Bradykinin</measure>
    <time_frame>up to 1 hour</time_frame>
    <description>Mean values of Bradykinin 1-8 and Bradykinin 1-7 will be calculated and reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean value of Angiontensin</measure>
    <time_frame>up to 1 hour</time_frame>
    <description>Mean values of Angiotensin I, Angiotensin II, Angiotensin IV, Angiotensin 1-7, Angiotensin 1-5, Angiotensin 1-9, Angiotensin 2-10, Angiotensin 2-7, and Angiotensin 3-7 will be calculated and reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean value of Aldosterone</measure>
    <time_frame>up to 1 hour</time_frame>
    <description>Mean value of Aldosterone will be calculated and reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Participants on ACE inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants taking ACE inhibitors (angiotensin-converting enzyme inhibitors)will be placed into this group. Intervention: Drug: Angiotensin II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants on ARBs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants taking ARBs (angiotensin-receptor blockers) will be placed into this group. Intervention: Drug: Angiotensin II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other Classes of Antihypertensive Agents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants taking any other class of Antihypertensive Agents will be placed into this group. Intervention: Drug: Angiotensin II.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin II</intervention_name>
    <description>Participants in the ACE inhibitors, ARBs, and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV. The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.</description>
    <arm_group_label>Other Classes of Antihypertensive Agents</arm_group_label>
    <arm_group_label>Participants on ACE inhibitors</arm_group_label>
    <arm_group_label>Participants on ARBs</arm_group_label>
    <other_name>Ang II</other_name>
    <other_name>Giapreza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hypertension and treatment with at least one medication including an ACE
             inhibitor, ARB, and other agents for greater than 2 months

          -  Patients undergoing general anesthesia

        Exclusion Criteria:

          -  BMI &gt; 40

          -  History of deep venous thrombosis / thromboembolic disease

          -  History of stroke,

          -  Baseline SBP of ≥ 160 mmHg,

          -  History of myocardial infarction or cardiac stents

          -  Difficult airway

          -  Asthma

          -  Congestive heart failure

          -  Chronic obstructive pulmonary disease

          -  Pregnant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rohesh Fernando, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Comfere T, Sprung J, Kumar MM, Draper M, Wilson DP, Williams BA, Danielson DR, Liedl L, Warner DO. Angiotensin system inhibitors in a general surgical population. Anesth Analg. 2005 Mar;100(3):636-44, table of contents.</citation>
    <PMID>15728043</PMID>
  </reference>
  <reference>
    <citation>Singh A, Antognini JF. Perioperative hypotension and myocardial ischemia: diagnostic and therapeutic approaches. Ann Card Anaesth. 2011 May-Aug;14(2):127-32. doi: 10.4103/0971-9784.81569. Review.</citation>
    <PMID>21636935</PMID>
  </reference>
  <reference>
    <citation>Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hästbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM; ATHOS-3 Investigators. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21.</citation>
    <PMID>28528561</PMID>
  </reference>
  <reference>
    <citation>Ferreira AJ, Murça TM, Fraga-Silva RA, Castro CH, Raizada MK, Santos RA. New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens. 2012;2012:147825. doi: 10.1155/2012/147825. Epub 2012 Jan 26.</citation>
    <PMID>22319643</PMID>
  </reference>
  <reference>
    <citation>Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, Seneff MG. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014 Oct 6;18(5):534. doi: 10.1186/s13054-014-0534-9.</citation>
    <PMID>25286986</PMID>
  </reference>
  <reference>
    <citation>Tallarida RJ, Stone DJ Jr, Raffa RB. Efficient designs for studying synergistic drug combinations. Life Sci. 1997;61(26):PL 417-25.</citation>
    <PMID>9416783</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angiotensin II</keyword>
  <keyword>Angiotensin Converting Enzyme Inhibitors</keyword>
  <keyword>Angiotensin Receptor Blockers</keyword>
  <keyword>Anesthesia-Mediated Hypotension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Giapreza</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

